The Institute for Clinical and Economic Review unveiled more details on its plans to evaluate whether price increases for "high-impact" drugs are justified by new clinical evidence.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,